Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ABT-639

Known as: T-type Calcium Channel Blocker ABT-639 
An orally bioavailable, CaV3.2 T-type calcium channel blocker with potential anti-hyperalgesic activity. Upon oral administration, ABT-639… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abdominal pain associated with low‐grade inflammation is frequently encountered in irritable bowel syndrome (IBS) and… Expand
Is this relevant?
2019
2019
BACKGROUND Doxorubicin (DOX) is an anticancer drug that has been widely used in the clinic. However, recently its application has… Expand
Is this relevant?
2017
2017
Low-voltage-activated calcium channels are important regulators of neurotransmission and membrane ion conductance. A plethora of… Expand
Is this relevant?
2016
2016
OBJECTIVE This randomized, double-blind, placebo-controlled, crossover trial evaluated the pharmacodynamic effects of a single… Expand
Is this relevant?
2015
2015
Abstract T-type calcium channels are a potential novel target for treatment of neuropathic pain such as painful diabetic… Expand
Is this relevant?
2015
2015
Abstract T-type Cav3.2 calcium channels represent a novel target for neuropathic pain modulation. Preclinical studies with ABT… Expand
Is this relevant?
2015
2015
The discovery of a novel peripherally acting and selective Cav3.2 T-type calcium channel blocker, ABT-639, is described. HTS hits… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2015
2015
ABT-639 is a selective T-type calcium channel blocker with efficacy in a wide range of preclinical models of nociceptive and… Expand
  • figure 1
  • table I
  • table II
  • table III
  • table IV
Is this relevant?
2014
2014
Activation of T-type Ca²⁺ channels contributes to nociceptive signaling by facilitating action potential bursting and modulation… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
ABT-639 is a selective T-type calcium channel blocker with efficacy in a wide range of preclinical models of nociceptive and… Expand
  • figure 1
  • table I
  • table II
  • table III
  • table IV
Is this relevant?